Literature DB >> 22129596

The role of β-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract.

Minho Kang1, Hercules T Maguma, Tricia H Smith, Gracious R Ross, William L Dewey, Hamid I Akbarali.   

Abstract

β-Arrestin2 has been reported to play an essential role in analgesic tolerance. Analgesic tolerance without concomitant tolerance to constipation is a limiting side effect of chronic morphine treatment. Because tolerance to morphine develops in the mouse ileum but not the colon, we therefore examined whether the role of β-arrestin2 in the mechanism of morphine tolerance differs in the ileum and colon. In both guinea pig and mouse, chronic in vitro exposure (2 h, 10 μM) to morphine resulted in tolerance development in the isolated ileum but not the colon. The IC(50) values for morphine-induced inhibition of electrical field stimulation contraction of guinea pig longitudinal muscle myenteric plexus shifted rightward in the ileum from 5.7 ± 0.08 (n = 9) to 5.45 ± 0.09 (n = 6) (p < 0.001) after morphine exposure. A significant shift was not observed in the colon. Similar differential tolerance was seen between the mouse ileum and the colon. However, tolerance developed in the colon from β-arrestin2 knockout mice. β-Arrestin2 and extracellular signal-regulated kinase 1/2 expression levels were determined further by Western blot analyses in guinea pig longitudinal muscle myenteric plexus. A time-dependent decrease in the expression of β-arrestin2 and extracellular signal-regulated kinase 1/2 occurred in the ileum but not the colon after 2 h of morphine (10 μM) exposure. Naloxone prevented the decrease in β-arrestin2. In the isolated ileum from guinea pigs chronically treated in vivo with morphine for 7 days, neither additional tolerance to in vitro exposure of morphine nor a decrease in β-arrestin2 occurred. We conclude that a decrease in β-arrestin2 is associated with tolerance development to morphine in the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129596      PMCID: PMC3286318          DOI: 10.1124/jpet.111.186320

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  32 in total

Review 1.  Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids.

Authors:  D A Taylor; W W Fleming
Journal:  J Pharmacol Exp Ther       Date:  2001-04       Impact factor: 4.030

Review 2.  Incidence, prevalence, and management of opioid bowel dysfunction.

Authors:  M Pappagallo
Journal:  Am J Surg       Date:  2001-11       Impact factor: 2.565

Review 3.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

4.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

5.  Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.

Authors:  L M Bohn; R R Gainetdinov; F T Lin; R J Lefkowitz; M G Caron
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

6.  Determination of the role of conventional, novel and atypical PKC isoforms in the expression of morphine tolerance in mice.

Authors:  Forrest L Smith; Bichoy H Gabra; Paul A Smith; Marcia C Redwood; William L Dewey
Journal:  Pain       Date:  2006-09-11       Impact factor: 6.961

7.  Morphine side effects in beta-arrestin 2 knockout mice.

Authors:  Kirsten M Raehal; Julia K L Walker; Laura M Bohn
Journal:  J Pharmacol Exp Ther       Date:  2005-05-25       Impact factor: 4.030

8.  Morphine tolerance in the mouse ileum and colon.

Authors:  Gracious R Ross; Bichoy H Gabra; William L Dewey; Hamid I Akbarali
Journal:  J Pharmacol Exp Ther       Date:  2008-08-05       Impact factor: 4.030

9.  Suppression of inhibitory neural input to colonic circular muscle by opioid peptides.

Authors:  J R Grider; G M Makhlouf
Journal:  J Pharmacol Exp Ther       Date:  1987-10       Impact factor: 4.030

10.  Beta-arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinase USP33 and the E3 ligase Mdm2.

Authors:  Sudha K Shenoy; Aalok S Modi; Arun K Shukla; Kunhong Xiao; Magali Berthouze; Seungkirl Ahn; Keith D Wilkinson; William E Miller; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-10       Impact factor: 11.205

View more
  30 in total

1.  17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.

Authors:  Yan Zhang; Dwight A Williams; Saheem A Zaidi; Yunyun Yuan; Amanda Braithwaite; Edward J Bilsky; William L Dewey; Hamid I Akbarali; John M Streicher; Dana E Selley
Journal:  ACS Chem Neurosci       Date:  2016-01-08       Impact factor: 4.418

2.  Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.

Authors:  Ahmad A Altarifi; Bethany David; Karan H Muchhala; Bruce E Blough; Hamid Akbarali; S Stevens Negus
Journal:  J Psychopharmacol       Date:  2017-02-01       Impact factor: 4.153

Review 3.  Efficacy and ligand bias at the μ-opioid receptor.

Authors:  E Kelly
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 4.  Site and mechanism of morphine tolerance in the gastrointestinal tract.

Authors:  H I Akbarali; A Inkisar; W L Dewey
Journal:  Neurogastroenterol Motil       Date:  2014-10       Impact factor: 3.598

Review 5.  The gut-brain interaction in opioid tolerance.

Authors:  Hamid I Akbarali; William L Dewey
Journal:  Curr Opin Pharmacol       Date:  2017-11-13       Impact factor: 5.547

6.  Inflammation-associated changes in DOR expression and function in the mouse colon.

Authors:  Jesse J DiCello; Ayame Saito; Pradeep Rajasekhar; Emily M Eriksson; Rachel M McQuade; Cameron J Nowell; Benjamin W Sebastian; Jakub Fichna; Nicholas A Veldhuis; Meritxell Canals; Nigel W Bunnett; Simona E Carbone; Daniel P Poole
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-21       Impact factor: 4.052

7.  6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.

Authors:  Yunyun Yuan; David L Stevens; Amanda Braithwaite; Krista L Scoggins; Edward J Bilsky; Hamid I Akbarali; William L Dewey; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2012-05-26       Impact factor: 2.823

8.  Inflammation-induced abnormalities in the subcellular localization and trafficking of the neurokinin 1 receptor in the enteric nervous system.

Authors:  Daniel P Poole; TinaMarie Lieu; Juan Carlos Pelayo; Emily M Eriksson; Nicholas A Veldhuis; Nigel W Bunnett
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-02       Impact factor: 4.052

Review 9.  Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities.

Authors:  Alfred D Nelson; Michael Camilleri
Journal:  Therap Adv Gastroenterol       Date:  2015-07       Impact factor: 4.409

Review 10.  β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  Handb Exp Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.